ECM/Integrin signaling promotes resistance to the combination of HER2 and PI3K inhibitors in HER2+, PIK3CA-mutant breast cancer

被引：0
|
作者：
Hanker, Ariella B.
Estrada, Monica Valeria
Zhao, Junfei
Cheng, Feixiong
Moore, Preston D.
Tyson, Darren
Sanchez, Violeta
Rexer, Brent N.
Sanders, Melinda
Zhao, Zhongming
Stricker, Thomas P.
Arteaga, Carlos L.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-302
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
302
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Interim safety analysis of phase IB trial of HER2 inhibitor tucatinib combined with PI3Kα inhibitor alpelisib in HER2+PIK3CA-mutated metastatic breast cancer.
    Gawryletz, Chelsea D.
    Dougherty-Gray, Colleen
    Datko, Farrah Mikhail
    Loch, Michelle Marie
    Sharifi, Marina
    Gopalakrishnan, Ragisha
    Kabos, Peter
    Borges, Virginia F.
    Shagisultanova, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Growth Suppression of HER2-Overexpressing Breast Cancer Cells by Berberine via Modulation of the HER2/PI3K/Akt Signaling Pathway
    Kuo, Han-Peng
    Chuang, Tzu-Chao
    Yeh, Ming-Han
    Hsu, Shih-Chung
    Way, Tzong-Der
    Chen, Po-Yuan
    Wang, Shan-Shue
    Chang, Yung-Hsien
    Kao, Ming-Ching
    Liu, Jah-Yao
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2011, 59 (15) : 8216 - 8224
  • [33] hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells
    P Trono
    F Di Modugno
    R Circo
    S Spada
    A Di Benedetto
    R Melchionna
    B Palermo
    S Matteoni
    S Soddu
    M Mottolese
    R De Maria
    P Nisticò
    Oncogene, 2016, 35 : 887 - 896
  • [34] Targeting PI3K and mTOR with BEZ235, a dual inhibitor, is efficacious in trastuzumab refractory and HER2+/PIK3CA-mutated breast cancer models
    Williams, Casey
    Sun, Yuliang
    Carlson, Jennifer
    Leyland-Jones, Brian
    Dey, Nandini
    De, Pradip
    CANCER RESEARCH, 2014, 74 (19)
  • [35] hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells
    Trono, P.
    Di Modugno, F.
    Circo, R.
    Spada, S.
    Di Benedetto, A.
    Melchionna, R.
    Palermo, B.
    Matteoni, S.
    Soddu, S.
    Mottolese, M.
    De Maria, R.
    Nistio, P.
    ONCOGENE, 2016, 35 (07) : 887 - 896
  • [36] Exon 9 and exon 20 mutations in PIK3CA confer resistance to HER2 inhibitors in HER2-overexpressing breast cancer cells.
    Rexer, B. N.
    Chakrabarty, A.
    Rinehart, C.
    Chang, J.
    Engelman, J.
    Arteaga, C. L.
    CANCER RESEARCH, 2009, 69 (02) : 266S - 267S
  • [37] Alpelisib in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2+, PIK3CA-mutant advanced breast cancer: EPIK-B2 Study Part 1 safety and efficacy results
    Hurvitz, Sara A.
    Bidard, Francois-Clement
    Li, Wei
    Hu, Xichun
    Pernas, Sonia
    Beck, Joseph Thaddeus
    Campone, Mario
    Punie, Kevin
    Miller, Michelle
    Kaper, Mathilde
    Han, Yu
    Ghaznawi, Farhat
    Jerusalem, Guy
    CANCER RESEARCH, 2023, 83 (07)
  • [38] More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro
    Zheng, Jie
    Wang, Huan
    Yao, Jia
    Zou, Xianjin
    PHARMAZIE, 2014, 69 (01): : 38 - 42
  • [39] Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
    Alessio Fiascarelli
    Giuseppe Merlino
    Stefania Capano
    Simone Talucci
    Diego Bisignano
    Alessandro Bressan
    Daniela Bellarosa
    Corrado Carrisi
    Alessandro Paoli
    Mario Bigioni
    Patrizia Tunici
    Clelia Irrissuto
    Massimiliano Salerno
    Joaquin Arribas
    Elisa de Stanchina
    Maurizio Scaltriti
    Monica Binaschi
    Breast Cancer Research and Treatment, 2023, 199 : 13 - 23
  • [40] DUAL-TARGETING OF AMPK AND PI3K/MTOR IN HER2 OVEREXPRESSING BREAST CANCER
    Russillo, Michelangelo
    Di Cosimo, Serena
    Serra, Violeta
    Scaltriti, Maurizio
    Rodriguez, Olga
    Cognetti, Francesco
    Baselga, Jose
    ANNALS OF ONCOLOGY, 2009, 20
12345